NASDAQ · BLRX
Healthcare · Biotechnology
$2.02
Up+$0.02 (+1.00%)
Updated Oct 30, 2026, 6:14 AM
SID Score
2.8/10
Composite research score
Smart Money
—
Institutional and insider signal
Price performance · BLRX
1M range · 21 trading sessions · Daily adjusted prices
Prices through Oct 29, 2026
BLRX closed at $2.02 after 21 trading sessions, down 14.04% for the selected period.
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Oct 29, 2026 | $2.01 | $2.02 | $1.94 | $2.02 | 4.15K |
| Oct 28, 2026 | $1.94 | $2.04 | $1.94 | $2.00 | 4.04K |
| Oct 27, 2026 | $1.97 | $2.03 | $1.96 | $2.03 | 4.99K |
| Oct 26, 2026 | $2.15 | $2.15 | $1.98 | $2.01 | 8.04K |
| Oct 23, 2026 | $2.04 | $2.11 | $2.04 | $2.04 | 1.7K |
| Oct 22, 2026 | $2.07 | $2.166 | $1.99 | $2.0635 | 5.2K |
| Oct 21, 2026 | $2.19 | $2.19 | $1.96 | $2.11 | 1.86K |
| Oct 20, 2026 | $2.07 | $2.2145 | $2.07 | $2.2145 | 3.06K |
| Oct 19, 2026 | $2.07 | $2.1599 | $1.96 | $1.98 | 34.66K |
| Oct 16, 2026 | $2.30 | $2.30 | $1.985 | $2.01 | 12.58K |
| Oct 15, 2026 | $2.03 | $2.165 | $1.945 | $2.05 | 28.75K |
| Oct 14, 2026 | $2.18 | $2.18 | $2.0101 | $2.075 | 23.53K |
| Oct 13, 2026 | $2.27 | $2.27 | $2.11 | $2.17 | 11.75K |
| Oct 12, 2026 | $2.22 | $2.3443 | $2.14 | $2.17 | 28.17K |
| Oct 9, 2026 | $2.20 | $2.2703 | $2.20 | $2.216 | 9.69K |
| Oct 8, 2026 | $2.31 | $2.31 | $2.17 | $2.21 | 18.37K |
| Oct 7, 2026 | $2.28 | $2.3698 | $2.16 | $2.205 | 24.04K |
| Oct 6, 2026 | $2.31 | $2.40 | $2.26 | $2.2922 | 22.87K |
| Oct 5, 2026 | $2.36 | $2.36 | $2.29 | $2.32 | 20.26K |
| Oct 2, 2026 | $2.31 | $2.37 | $2.31 | $2.37 | 3.13K |
| Oct 1, 2026 | $2.32 | $2.3886 | $2.32 | $2.35 | 7.58K |
The latest Smart Investors Daily articles mentioning BLRX.
Company
Market Activity
Research & News
BLRX research
Company profile and research snapshot.
BioLine Rx Ltd is a commercial-stage biopharmaceutical company focused on oncology. The company's current development and commercialization pipeline consists of two clinical-stage therapeutic candidates motixafortide (BL-8040), a novel peptide for the treatment of stem-cell mobilization and solid tumors, and AGI-134, an immuno-oncology agent in development for solid tumors. In addition, the company has a legacy therapeutic product called BL-5010 for the treatment of skin lesions. The company has generated revenues from milestone payments under previously existing out-licensing agreements.
Visit company websiteConsensus and target data currently published for this company.
| Date | Firm | Rating | Target |
|---|---|---|---|
| Dec 16, 2020 | HC Wainwright & Co. | Buy | — |
| Aug 4, 2017 | Oppenheimer | Outperform | — |
| May 18, 2017 | Maxim Group | Buy | — |
| Feb 13, 2017 | Rodman & Renshaw | Buy | — |
No generated briefing is available yet.
Benzinga · Oct 23, 2026
GLIX1 demonstrated reproducible synergy across different PARP inhibitors and multiple HR-proficient ovarian cancer cell lines, with high ZIP synergy scores, highlighting GLIX1's potential to expand the efficacy of
Yahoo · Oct 8, 2026
BioLineRx Ltd. (NASDAQ: BLRX) (TASE: BLRX), a clinical-stage biopharmaceutical company pursuing life-changing therapies in oncology and rare diseases, and Hemispherian AS, a clinical-stage oncology company developing novel small molecule therapeutics, today announced that two abstracts featuring GLIX1 will be presented at the 31st Society for Neuro-Oncology (SNO) Annual Meeting & Education Day, taking place November 12-15 in Philadelphia, Pennsylvania.
Benzinga · Oct 8, 2026
The presentations will highlight preclinical research evaluating GLIX1 across multiple glioblastoma models, as well as the design of the ongoing Phase 1/2a clinical trial evaluating GLIX1 in patients with recurrent or
Yahoo · Sep 10, 2026
BioLineRx Ltd. (NASDAQ: BLRX) (TASE: BLRX), a clinical-stage biopharmaceutical company pursuing life-changing therapies in oncology and rare diseases, and Hemispherian AS, a clinical-stage oncology company developing novel small molecule therapeutics, today announced that two abstracts featuring GLIX1 have been accepted for presentation, including one selected for oral presentation highlighting the preclinical efficacy of GLIX1 in orthotopic glioblastoma models, at the 21st Meeting of the Europe
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
The latest Smart Investors Daily articles mentioning BLRX.
No results
No recent SID articles mention BLRX.
